BMYMirati Therapeutics Inc.Running, no new patients
Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation
Metastatic Non Small Cell Lung Cancer · Advanced Non Small Cell Lung Cancer
3Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2.6
2 insiders sold shares within a month
Since Sep 9, 2026 · was worth 5, fading over time
Worry score3
Score over time
- Stage
- Phase 3
- Patients
- 453 (final count)
- Started
- Feb 23, 2021
- Main results expected
- Dec 30, 2023
- Fully finished
- Oct 30, 2026
- Results posted
- Jan 22, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-Free Survival (PFS) as Per Blinded Independent Central Review
Measured over: From randomization to the date of progression or death due to any cause, whichever occurs first (up to approximately 143 weeks)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2.6, since 2026-09-09, fades (half-life)
Raw record changes
- none yet
Trial ID NCT04685135 · record last updated 2026-08-11 · checked 2026-11-09 15:47 UTC